UNSPSC 51343404: Celgosivir

This classification denotes a glucosidase inhibitor and antiviral agent with the molecular formula C12H21NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 895VG117HN, chemically known as mdl 28,574a but generally known as celgosivir, which bears US NIH Compound Identifier 60734. European Medicines Agency schedules Celgosivir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07435MIG.

UNSPSC 51343404 Celgosivir is a Commodity code that does not reflect the work actually being solicited under it in recent state and local procurement. The posted opportunities tagged to this code involve naloxone and drug deactivation systems, therapeutic pharmacy initiatives, medical and first aid supplies for fire rescue operations, and generic pharmaceuticals and over-the-counter products — none of which are celgosivir, an antiviral hepatitis C compound. The tagging mismatch suggests either a system classification error or a code designation that has drifted from current procurement practice. State and local governments buying under this code designation are acquiring emergency medical supplies, pharmaceutical products through cooperative purchasing arrangements, and pharmacy benefit program support rather than the specific antiviral agent the code name denotes.

Recent opportunities span multiple issuing-body types. Seminole County, Florida posted an IFB for naloxone and drug deactivation systems (1,900 units of naloxone and 800 deactivation systems annually) with a response deadline of July 26, 2023. The City of Tampa issued an IFB for medical and first aid supplies for the Tampa Fire Department Rescue Division with a $700,000 estimated contract value and a March 13, 2026 deadline, designated as a sheltered market for certified Small Local Business Enterprises with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, solicited generic multi-source pharmaceuticals and over-the-counter products through an RFP due March 26, 2026, serving participating state and local government facilities including Oregon. Texas Health and Human Services Commission issued an RFI for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program with an April 3, 2026 response deadline. Activity concentrates in Florida, Texas, and Minnesota with cooperative purchasing vehicles extending coverage across multiple states. The code shows substantial recent activity but lacks clarity in scope alignment with the nominal commodity definition.